Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$61.55

1.41 (2.34%)

, NBIX

Neurocrine

$44.59

2.29 (5.41%)

09:02
10/19/16
10/19
09:02
10/19/16
09:02

AbbVie reports 'positive' Phase 3 data from Elagolix trials

AbbVie (ABBV) in cooperation with Neurocrine Biosciences (NBIX) announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain and non-menstrual pelvic pain associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. The results were presented at the 72nd American Society for Reproductive Medicine Scientific Congress & Expo in Salt Lake City, as well as additional abstracts. In the two studies, both doses of Elagolix administered orally demonstrated a statistically significant (p less than or equal to 0.001) improvement versus placebo in the percentage of DYS and NMPP responders. In the first study, at month three, 46 percent of patients treated with 150 mg once daily and 76 percent of patients treated with 200 mg twice daily of Elagolix were classified as DYS responders, versus 20 percent of patients in the placebo group. Fifty percent of patients treated with 150 mg once daily and 55 percent of patients treated with 200 mg twice daily of Elagolix were classified as NMPP responders, versus 36 percent of patients in the placebo group. The second pivotal Phase 3 study demonstrated similar results.

ABBV

AbbVie

$61.55

1.41 (2.34%)

NBIX

Neurocrine

$44.59

2.29 (5.41%)

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 28

    Oct

  • 06

    Nov

  • 11

    Nov

  • 29

    Nov

  • 14

    Dec

ABBV AbbVie
$61.55

1.41 (2.34%)

10/18/16
LEER
10/18/16
INITIATION
Target $70
LEER
Market Perform
AbbVie initiated with a Market Perform at Leerink
Leerink analyst Geoffrey Porges started AbbVie with a Market Perform rating and $70 price target. The analyst sees "significant uncertainty" about the durability of the company's dominant franchise, Humira.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Outperform
Vertex competitor to report data soon, but has long way to go, says RBC Capital
RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
NBIX Neurocrine
$44.59

2.29 (5.41%)

10/18/16
NEED
10/18/16
INITIATION
Target $62
NEED
Buy
Neurocrine initiated with a Buy at Needham
Needham analyst Alan Carr initiated Neurocrine with a Buy and a $62 price target.
10/13/16
BMOC
10/13/16
NO CHANGE
BMOC
Neurocrine recent weakness unwarranted, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that Neurocrine (NBIX) has been weak recently in the wake of Myovant's S-1 filing. According to the analyst, investors view Myovant's relugolix as a more convenient alternative to Neurocrine's elagolix. However, the analyst thinks that relugolix's longer half-life "could complicate add-back therapy," while the wording of the questionnaire for relugolix's Phase 3 trial increases endometriosis clinical development risk. Additionally, the analyst says that Neurocrine's elagolix has a two to three year lead time over relugolix, setting the stage for both drugs to do well. He keeps a $66 price target and Outperform rating on Neurocrine.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.

TODAY'S FREE FLY STORIES

ORI

Old Republic

$20.22

0.15 (0.75%)

09:04
04/27/17
04/27
09:04
04/27/17
09:04
Earnings
Old Republic reports Q1 EPS 39c, consensus 31c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$11.60

0.12 (1.05%)

09:04
04/27/17
04/27
09:04
04/27/17
09:04
Hot Stocks
Ford says 'fit' for any future downturn in North America »

Comments taken from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

UPS

UPS

$107.62

0.26 (0.24%)

09:04
04/27/17
04/27
09:04
04/27/17
09:04
Hot Stocks
Breaking Hot Stocks news story on UPS »

UPS says Q1 pricing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

ANTM

Anthem

$179.03

6.57 (3.81%)

, CVS

CVS Health

$82.00

-0.17 (-0.21%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Recommendations
Anthem, CVS Health, Express Scripts analyst commentary  »

Anthem price target…

ANTM

Anthem

$179.03

6.57 (3.81%)

CVS

CVS Health

$82.00

-0.17 (-0.21%)

ESRX

Express Scripts

$61.28

1.27 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

  • 18

    May

  • 06

    Jun

CBS

CBS

$66.91

0.5 (0.75%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Recommendations
CBS analyst commentary  »

CBS valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 08

    May

  • 15

    Jun

GRUB

GrubHub

$35.02

0.24 (0.69%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Earnings
GrubHub sees FY17 revenue $632M-$662M, consensus $644.39M »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

  • 24

    May

  • 25

    May

BANC

Banc of California

$22.45

-0.15 (-0.66%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Hot Stocks
Banc of California names Doug Bowers as CEO, effective May 8 »

Banc of California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ORRF

Orrstown Financial

$21.95

-0.45 (-2.01%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Earnings
Orrstown Financial reports Q1 EPS 24c, consensus 20c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

GRUB

GrubHub

$35.02

0.24 (0.69%)

09:02
04/27/17
04/27
09:02
04/27/17
09:02
Earnings
GrubHub sees Q2 revenue $153M-$161M, consensus $157.95M »

Sees Q2 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

  • 24

    May

  • 25

    May

GRUB

GrubHub

$35.02

0.24 (0.69%)

09:01
04/27/17
04/27
09:01
04/27/17
09:01
Earnings
GrubHub reports Q1 non-GAAP EPS 29c, consensus 24c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

  • 24

    May

  • 25

    May

DISCA

Discovery

$29.39

0.1 (0.34%)

09:00
04/27/17
04/27
09:00
04/27/17
09:00
Periodicals
Discovery Asia partners with VS Media, Tabilabo, Variety says »

Discovery Networks Asia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 08

    May

  • 18

    May

  • 31

    May

CNMD

CONMED

$48.13

0.93 (1.97%)

09:00
04/27/17
04/27
09:00
04/27/17
09:00
Recommendations
CONMED analyst commentary  »

CONMED price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

09:00
04/27/17
04/27
09:00
04/27/17
09:00
Hot Stocks
Under Armour CFO sees Q4 to be strongest comparison of 2017 'by far' »

Under Armour CFO David…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

09:00
04/27/17
04/27
09:00
04/27/17
09:00
General news
U.S. Advance trade deficit in goods widened slightly to -$64.8 B »

U.S. Advance trade…

SNCR

Synchronoss

$24.62

-0.02 (-0.08%)

09:00
04/27/17
04/27
09:00
04/27/17
09:00
Hot Stocks
Breaking Hot Stocks news story on Synchronoss »

Synchronoss trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

BGSF

BG Staffing

$15.15

-0.27 (-1.75%)

08:58
04/27/17
04/27
08:58
04/27/17
08:58
Earnings
BG Staffing reports Q1 EPS 15c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

TMO

Thermo Fisher

$168.01

9.2 (5.79%)

08:58
04/27/17
04/27
08:58
04/27/17
08:58
Recommendations
Thermo Fisher analyst commentary  »

Thermo Fisher price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 06

    Jun

SNBC

Sun Bancorp

$25.70

-0.05 (-0.19%)

08:57
04/27/17
04/27
08:57
04/27/17
08:57
Earnings
Sun Bancorp reports Q1 EPS 7c, consensus 8c »

Reports Q1 NII $14.78M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 15

    May

UPS

UPS

$107.62

0.26 (0.24%)

08:57
04/27/17
04/27
08:57
04/27/17
08:57
Hot Stocks
UPS says sees margin improvement in 2017 »

Expects revenue to grow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

RTN

Raytheon

$155.27

-0.74 (-0.47%)

08:56
04/27/17
04/27
08:56
04/27/17
08:56
Hot Stocks
Raytheon raises FY17 EPS view to $7.25-$7.40 from $7.20-$7.35, consensus $7.40 »

Raises FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

BA

Boeing

$181.71

-1.8 (-0.98%)

08:56
04/27/17
04/27
08:56
04/27/17
08:56
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

EXAS

Exact Sciences

$23.80

-1.09 (-4.38%)

08:56
04/27/17
04/27
08:56
04/27/17
08:56
Recommendations
Exact Sciences analyst commentary  »

Exact Sciences Q1 report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 30

    May

  • 06

    Jun

AA

Alcoa

$36.45

-0.04 (-0.11%)

08:56
04/27/17
04/27
08:56
04/27/17
08:56
Syndicate
Alcoa 12.959M share Spot Secondary priced at $36.15 »

Citi and Credit Suisse…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

X

U.S. Steel

$22.78

-8.33 (-26.78%)

, NSC

Norfolk Southern

$117.82

1.04 (0.89%)

08:56
04/27/17
04/27
08:56
04/27/17
08:56
Options
Notable open interest changes for April 27th »

Wednesday's total…

X

U.S. Steel

$22.78

-8.33 (-26.78%)

NSC

Norfolk Southern

$117.82

1.04 (0.89%)

BAC

Bank of America

$23.89

-0.09 (-0.38%)

TWTR

Twitter

$15.82

1.16 (7.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 11

    May

  • 31

    May

  • 06

    Jun

CTB

Cooper Tire

$43.40

0.05 (0.12%)

08:55
04/27/17
04/27
08:55
04/27/17
08:55
Technical Analysis
Cooper Tire drops sharply after earnings miss »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 18

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.